Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiromic BioPharma, Inc. - Common Stock (NQ: KRBP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiromic BioPharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
Live and Archived Fireside Chat Available at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Uplisting to OTCQB Market
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
From Kiromic BioPharma
Via Business Wire
Kiromic BioPharma Welcomes Two New Directors to its Board
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Reverse Stock Split
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
From Kiromic BioPharma, Inc.
Via Business Wire
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma CEO Issues Letter to Stockholders
From Kiromic BioPharma, Inc.
Via Business Wire
NASDAQ:KRBP Long Term Investor Alert: Investigation over Possible Wrongdoing at Kiromic BioPharma, Inc.
San Diego, CA -- (SBWIRE) -- 11/09/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Kiromic BioPharma, Inc.. 
Via SBWire
Kiromic BioPharma Arranges Up to $10 Million Financing
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
From Kiromic BioPharma, Inc.
Via Business Wire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.